Details of the Drug

General Information of Drug (ID: DMSOURV)

• Drug Name: Formoterol
• Synonyms: Foradile; Formoterol tartrate; Oxeze Turbuhaler Foradil; MOLI000351; Atimos (TN); Atock (TN); Foradil (TN); Foradile (TN); Formoterol (INN); Modulite (TN); Oxeze (TN); Oxis (TN); Perforomist (TN); Formoterol, ((R*,R*)-(+-)-)-isomer; N-[2-hydroxy-5-[1-hydroxy-2-[1-(4-methoxyphenyl)propan-2-ylamino]ethyl]phenyl]formamide; N-[2-hydroxy-5-(1-hydroxy-2-{[1-(4-methoxyphenyl)propan-2-yl]amino}ethyl)phenyl]formamide; N-[2-hydroxy-5-[(1R)-1-hydroxy-2-[[(2S)-1-(4-methoxyphenyl)propan-2-yl]amino]ethyl]phenyl]formamide; (+-)-2'-Hydroxy-5'-((RS)-1-hydroxy-2-(((RS)-p-methoxy-alpha-methylphenethyl)amino)ethyl)formanilide; 3-formylamino-4-hydroxy-alpha-(N-1-methyl-2-p-methoxyphenethylaminomethyl)benzyl alcohol.hemifumarate

Indication

Disease Entry	ICD 11	Status	REF
Asthma	CA23	Approved	[1], [2]

• Therapeutic Class: Sympathomimetics
• Drug Type: Small molecular drug
• #Ro5 Violations (Lipinski): 0:
  Molecular Weight (mw); 344.4
  Topological Polar Surface Area (xlogp); 1.8
  Rotatable Bond Count (rotbonds); 8
  Hydrogen Bond Donor Count (hbonddonor); 4
  Hydrogen Bond Acceptor Count (hbondacc); 5
• ADMET Property:
  Absorption AUC: The area under the plot of plasma concentration (AUC) of drug is 0.000081 micromolh/L [3]
  Absorption Tmax: The time to maximum plasma concentration (Tmax) is 0.167-0.5 h [3]
  Bioavailability: The bioavailability of drug is 43% [3]
  Clearance: The renal clearance of drug is 157 mL/min [4]
  Elimination: Following oral administration in 2 healthy subjects, approximately 59-62% and 32-34% of an administered dose was eliminated in the urine and feces, respectively [5]
  Half-life: The concentration or amount of drug in body reduced by one-half in 7 - 10 hours [6]
  Metabolism: The drug is metabolized via the direct glucuronidation of the parent drug and via O-demethylation of the parent drug followed by glucuronidation [4]
• Chemical Identifiers:
  Formula: C19H24N2O4
  IUPAC Name: N-[2-hydroxy-5-[1-hydroxy-2-[1-(4-methoxyphenyl)propan-2-ylamino]ethyl]phenyl]formamide
  Canonical SMILES: CC(CC1=CC=C(C=C1)OC)NCC(C2=CC(=C(C=C2)O)NC=O)O
  InChI: InChI=1S/C19H24N2O4/c1-13(9-14-3-6-16(25-2)7-4-14)20-11-19(24)15-5-8-18(23)17(10-15)21-12-22/h3-8,10,12-13,19-20,23-24H,9,11H2,1-2H3,(H,21,22)
  InChIKey: BPZSYCZIITTYBL-UHFFFAOYSA-N
• Cross-matching ID:
  PubChem CID: 3410
  ChEBI ID: CHEBI:63082
  CAS Number: 73573-87-2
  DrugBank ID: DB00983
  TTD ID: D04KJO
  VARIDT ID: DR01355
  INTEDE ID: DR0744

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Adrenergic receptor beta-2 (ADRB2)	TT2CJVK	ADRB2_HUMAN	Agonist	[7], [8], [9]

Drug Transporter (DTP)

DTP Name	DTP ID	UniProt ID	MOA	REF
Organic cation transporter 1 (SLC22A1)	DTT79CX	S22A1_HUMAN	Substrate	[10]

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Cytochrome P450 2D6 (CYP2D6) Main DME	DECB0K3	CP2D6_HUMAN	Substrate	[11]
Cytochrome P450 2C9 (CYP2C9) Main DME	DE5IED8	CP2C9_HUMAN	Substrate	[12]
Mephenytoin 4-hydroxylase (CYP2C19) Main DME	DEGTFWK	CP2CJ_HUMAN	Substrate	[11]

Molecular Expression Atlas of This Drug

• The Studied Disease: Asthma
• ICD Disease Classification: CA23

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Adrenergic receptor beta-2 (ADRB2)	DTT	ADRB2	4.88E-01	-0.05	-0.12
Adrenergic receptor beta-2 (ADRB2)	DTT	ADRB2	7.10E-01	0.06	0.09
Organic cation transporter 1 (SLC22A1)	DTP	SLC22A1	1.48E-01	6.33E-02	3.20E-01
Organic cation transporter 1 (SLC22A1)	DTP	SLC22A1	1.74E-02	1.21E-01	4.40E-01
Mephenytoin 4-hydroxylase (CYP2C19)	DME	CYP2C19	4.79E-03	1.32E-01	7.85E-01
Mephenytoin 4-hydroxylase (CYP2C19)	DME	CYP2C19	1.82E-01	-1.71E-02	-9.86E-02
Cytochrome P450 2D6 (CYP2D6)	DME	CYP2D6	8.01E-02	6.73E-02	3.36E-01
Cytochrome P450 2D6 (CYP2D6)	DME	CYP2D6	2.91E-04	1.41E-01	6.14E-01
Cytochrome P450 2C9 (CYP2C9)	DME	CYP2C9	7.33E-02	5.59E-02	2.99E-01
Cytochrome P450 2C9 (CYP2C9)	DME	CYP2C9	5.65E-03	-7.28E-02	-1.24E-01

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Formoterol

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Disease	REF
Budesonide	DMJIBAW	Minor	Increased risk of hypokalemia by the combination of Formoterol and Budesonide.	Asthma [CA23]	[59]

Coadministration of a Drug Treating the Disease Different from Formoterol (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Methylene blue	DMJAPE7	Moderate	Additive hypertensive effects by the combination of Formoterol and Methylene blue.	Acquired methaemoglobinaemia [3A93]	[60]
Ivosidenib	DM8S6T7	Moderate	Increased risk of ventricular arrhythmias by the combination of Formoterol and Ivosidenib.	Acute myeloid leukaemia [2A60]	[61]
Midostaurin	DMI6E0R	Moderate	Increased risk of prolong QT interval by the combination of Formoterol and Midostaurin.	Acute myeloid leukaemia [2A60]	[61]
Idarubicin	DMM0XGL	Moderate	Increased risk of ventricular arrhythmias by the combination of Formoterol and Idarubicin.	Acute myeloid leukaemia [2A60]	[61]
Arn-509	DMT81LZ	Moderate	Increased risk of ventricular arrhythmias by the combination of Formoterol and Arn-509.	Acute myeloid leukaemia [2A60]	[61]
Gilteritinib	DMWQ4MZ	Moderate	Increased risk of prolong QT interval by the combination of Formoterol and Gilteritinib.	Acute myeloid leukaemia [2A60]	[61]
Oliceridine	DM6MDCF	Moderate	Increased risk of prolong QT interval by the combination of Formoterol and Oliceridine.	Acute pain [MG31]	[61]
Ivabradine	DM0L594	Moderate	Increased risk of ventricular arrhythmias by the combination of Formoterol and Ivabradine.	Angina pectoris [BA40]	[61]
Bepridil	DM0RKS4	Moderate	Increased risk of prolong QT interval by the combination of Formoterol and Bepridil.	Angina pectoris [BA40]	[61]
Bedaquiline	DM3906J	Moderate	Increased risk of ventricular arrhythmias by the combination of Formoterol and Bedaquiline.	Antimicrobial drug resistance [MG50-MG52]	[61]
Cilostazol	DMZMSCT	Moderate	Increased risk of ventricular arrhythmias by the combination of Formoterol and Cilostazol.	Arterial occlusive disease [BD40]	[61]
Posaconazole	DMUL5EW	Moderate	Increased risk of ventricular arrhythmias by the combination of Formoterol and Posaconazole.	Aspergillosis [1F20]	[61]
Lisdexamfetamine	DM6W8V5	Moderate	Increased risk of prolong QT interval by the combination of Formoterol and Lisdexamfetamine.	Attention deficit hyperactivity disorder [6A05]	[61]
Droxidopa	DM5YF4M	Moderate	Additive hypertensive effects by the combination of Formoterol and Droxidopa.	Autonomic nervous system disorder [8D87]	[62]
Ofloxacin	DM0VQN3	Moderate	Increased risk of ventricular arrhythmias by the combination of Formoterol and Ofloxacin.	Bacterial infection [1A00-1C4Z]	[61]
Clarithromycin	DM4M1SG	Moderate	Increased risk of prolong QT interval by the combination of Formoterol and Clarithromycin.	Bacterial infection [1A00-1C4Z]	[61]
Gemifloxacin	DMHT34O	Moderate	Increased risk of ventricular arrhythmias by the combination of Formoterol and Gemifloxacin.	Bacterial infection [1A00-1C4Z]	[61]
Norfloxacin	DMIZ6W2	Moderate	Increased risk of prolong QT interval by the combination of Formoterol and Norfloxacin.	Bacterial infection [1A00-1C4Z]	[61]
Levofloxacin	DMS60RB	Moderate	Increased risk of ventricular arrhythmias by the combination of Formoterol and Levofloxacin.	Bacterial infection [1A00-1C4Z]	[61]
Retigabine	DMGNYIH	Moderate	Increased risk of ventricular arrhythmias by the combination of Formoterol and Retigabine.	Behcet disease [4A62]	[61]
Eribulin	DM1DX4Q	Moderate	Increased risk of ventricular arrhythmias by the combination of Formoterol and Eribulin.	Breast cancer [2C60-2C6Y]	[61]
Lapatinib	DM3BH1Y	Moderate	Increased risk of ventricular arrhythmias by the combination of Formoterol and Lapatinib.	Breast cancer [2C60-2C6Y]	[61]
Bosutinib	DMTI8YE	Moderate	Increased risk of prolong QT interval by the combination of Formoterol and Bosutinib.	Breast cancer [2C60-2C6Y]	[61]
Corticotropin	DMP9TWZ	Minor	Increased risk of hypokalemia by the combination of Formoterol and Corticotropin.	Chronic kidney disease [GB61]	[59]
PF-04449913	DMSB068	Moderate	Increased risk of prolong QT interval by the combination of Formoterol and PF-04449913.	Chronic myelomonocytic leukaemia [2A40]	[61]
Levomilnacipran	DMV26S8	Moderate	Additive hypertensive effects by the combination of Formoterol and Levomilnacipran.	Chronic pain [MG30]	[63]
Halothane	DM80OZ5	Moderate	Increased risk of prolong QT interval by the combination of Formoterol and Halothane.	Corneal disease [9A76-9A78]	[61]
Sevoflurane	DMC9O43	Moderate	Increased risk of ventricular arrhythmias by the combination of Formoterol and Sevoflurane.	Corneal disease [9A76-9A78]	[61]
Probucol	DMVZQ2M	Moderate	Increased risk of ventricular arrhythmias by the combination of Formoterol and Probucol.	Coronary atherosclerosis [BA80]	[61]
Pasireotide	DMHM7JS	Moderate	Increased risk of ventricular arrhythmias by the combination of Formoterol and Pasireotide.	Cushing syndrome [5A70]	[61]
Osilodrostat	DMIJC9X	Moderate	Increased risk of ventricular arrhythmias by the combination of Formoterol and Osilodrostat.	Cushing syndrome [5A70]	[61]
Sertraline	DM0FB1J	Moderate	Increased risk of ventricular arrhythmias by the combination of Formoterol and Sertraline.	Depression [6A70-6A7Z]	[61]
Selegiline	DM6034S	Moderate	Additive hypertensive effects by the combination of Formoterol and Selegiline.	Depression [6A70-6A7Z]	[60]
Isocarboxazid	DMAF1NB	Moderate	Additive hypertensive effects by the combination of Formoterol and Isocarboxazid.	Depression [6A70-6A7Z]	[60]
Milnacipran	DMBFE74	Moderate	Increased risk of rapid heart rate by the combination of Formoterol and Milnacipran.	Depression [6A70-6A7Z]	[63]
Escitalopram	DMFK9HG	Moderate	Increased risk of ventricular arrhythmias by the combination of Formoterol and Escitalopram.	Depression [6A70-6A7Z]	[61]
Desvenlafaxine	DMHD4PE	Moderate	Increased risk of rapid heart rate by the combination of Formoterol and Desvenlafaxine.	Depression [6A70-6A7Z]	[63]
Tetrabenazine	DMYWQ0O	Moderate	Increased risk of prolong QT interval by the combination of Formoterol and Tetrabenazine.	Dissociative neurological symptom disorder [6B60]	[61]
Deutetrabenazine	DMUPFLI	Moderate	Increased risk of prolong QT interval by the combination of Formoterol and Deutetrabenazine.	Dystonic disorder [8A02]	[61]
Ingrezza	DMVPLNC	Moderate	Increased risk of prolong QT interval by the combination of Formoterol and Ingrezza.	Dystonic disorder [8A02]	[61]
Solifenacin	DMG592Q	Moderate	Increased risk of ventricular arrhythmias by the combination of Formoterol and Solifenacin.	Functional bladder disorder [GC50]	[61]
Ketoconazole	DMPZI3Q	Moderate	Increased risk of ventricular arrhythmias by the combination of Formoterol and Ketoconazole.	Fungal infection [1F29-1F2F]	[61]
Sunitinib	DMCBJSR	Moderate	Increased risk of ventricular arrhythmias by the combination of Formoterol and Sunitinib.	Gastrointestinal stromal tumour [2B5B]	[61]
Procarbazine	DMIK367	Moderate	Additive hypertensive effects by the combination of Formoterol and Procarbazine.	Hodgkin lymphoma [2B30]	[60]
Saquinavir	DMG814N	Moderate	Increased risk of ventricular arrhythmias by the combination of Formoterol and Saquinavir.	Human immunodeficiency virus disease [1C60-1C62]	[61]
Lopinavir	DMITQS0	Moderate	Increased risk of prolong QT interval by the combination of Formoterol and Lopinavir.	Human immunodeficiency virus disease [1C60-1C62]	[64]
Rilpivirine	DMJ0QOW	Moderate	Increased risk of ventricular arrhythmias by the combination of Formoterol and Rilpivirine.	Human immunodeficiency virus disease [1C60-1C62]	[61]
Crizotinib	DM4F29C	Moderate	Increased risk of prolong QT interval by the combination of Formoterol and Crizotinib.	Lung cancer [2C25]	[61]
Ceritinib	DMB920Z	Moderate	Increased risk of prolong QT interval by the combination of Formoterol and Ceritinib.	Lung cancer [2C25]	[61]
Osimertinib	DMRJLAT	Moderate	Increased risk of ventricular arrhythmias by the combination of Formoterol and Osimertinib.	Lung cancer [2C25]	[61]
Selpercatinib	DMZR15V	Moderate	Increased risk of ventricular arrhythmias by the combination of Formoterol and Selpercatinib.	Lung cancer [2C25]	[61]
Lumefantrine	DM29GAD	Moderate	Increased risk of prolong QT interval by the combination of Formoterol and Lumefantrine.	Malaria [1F40-1F45]	[64]
Halofantrine	DMOMK1V	Moderate	Increased risk of ventricular arrhythmias by the combination of Formoterol and Halofantrine.	Malaria [1F40-1F45]	[61]
Hydroxychloroquine	DMSIVND	Moderate	Increased risk of prolong QT interval by the combination of Formoterol and Hydroxychloroquine.	Malaria [1F40-1F45]	[61]
Primaquine	DMWQ16I	Moderate	Increased risk of ventricular arrhythmias by the combination of Formoterol and Primaquine.	Malaria [1F40-1F45]	[61]
Inotuzumab ozogamicin	DMAC130	Moderate	Increased risk of prolong QT interval by the combination of Formoterol and Inotuzumab ozogamicin.	Malignant haematopoietic neoplasm [2B33]	[61]
Arsenic trioxide	DM61TA4	Moderate	Increased risk of prolong QT interval by the combination of Formoterol and Arsenic trioxide.	Mature B-cell lymphoma [2A85]	[61]
Vemurafenib	DM62UG5	Moderate	Increased risk of prolong QT interval by the combination of Formoterol and Vemurafenib.	Melanoma [2C30]	[61]
LGX818	DMNQXV8	Moderate	Increased risk of ventricular arrhythmias by the combination of Formoterol and LGX818.	Melanoma [2C30]	[61]
Panobinostat	DM58WKG	Moderate	Increased risk of prolong QT interval by the combination of Formoterol and Panobinostat.	Multiple myeloma [2A83]	[61]
Siponimod	DM2R86O	Moderate	Increased risk of prolong QT interval by the combination of Formoterol and Siponimod.	Multiple sclerosis [8A40]	[61]
Fingolimod	DM5JVAN	Moderate	Increased risk of ventricular arrhythmias by the combination of Formoterol and Fingolimod.	Multiple sclerosis [8A40]	[61]
Ozanimod	DMT6AM2	Major	Increased risk of ventricular arrhythmias by the combination of Formoterol and Ozanimod.	Multiple sclerosis [8A40]	[65]
Romidepsin	DMT5GNL	Moderate	Increased risk of ventricular arrhythmias by the combination of Formoterol and Romidepsin.	Mycosis fungoides [2B01]	[61]
Dasatinib	DMJV2EK	Moderate	Increased risk of ventricular arrhythmias by the combination of Formoterol and Dasatinib.	Myeloproliferative neoplasm [2A20]	[61]
Promethazine	DM6I5GR	Moderate	Increased risk of prolong QT interval by the combination of Formoterol and Promethazine.	Nausea/vomiting [MD90]	[61]
Entrectinib	DMMPTLH	Moderate	Increased risk of prolong QT interval by the combination of Formoterol and Entrectinib.	Non-small cell lung cancer [2C25]	[61]
Sibutramine	DMFJTDI	Moderate	Increased risk of rapid heart rate by the combination of Formoterol and Sibutramine.	Obesity [5B80-5B81]	[66]
Levomethadyl Acetate	DM06HG5	Moderate	Increased risk of prolong QT interval by the combination of Formoterol and Levomethadyl Acetate.	Opioid use disorder [6C43]	[64]
Lofexidine	DM1WXA6	Moderate	Increased risk of ventricular arrhythmias by the combination of Formoterol and Lofexidine.	Opioid use disorder [6C43]	[61]
Rucaparib	DM9PVX8	Moderate	Increased risk of prolong QT interval by the combination of Formoterol and Rucaparib.	Ovarian cancer [2C73]	[61]
Triclabendazole	DMPWGBR	Moderate	Increased risk of ventricular arrhythmias by the combination of Formoterol and Triclabendazole.	Parasitic worm infestation [1F90]	[61]
Safinamide	DM0YWJC	Moderate	Additive hypertensive effects by the combination of Formoterol and Safinamide.	Parkinsonism [8A00]	[60]
Rasagiline	DM3WKQ4	Moderate	Additive hypertensive effects by the combination of Formoterol and Rasagiline.	Parkinsonism [8A00]	[60]
Pimavanserin	DMR7IVC	Moderate	Increased risk of ventricular arrhythmias by the combination of Formoterol and Pimavanserin.	Parkinsonism [8A00]	[61]
Macimorelin	DMQYJIR	Major	Increased risk of prolong QT interval by the combination of Formoterol and Macimorelin.	Pituitary gland disorder [5A60-5A61]	[67]
Lefamulin	DME6G97	Moderate	Increased risk of ventricular arrhythmias by the combination of Formoterol and Lefamulin.	Pneumonia [CA40]	[61]
Degarelix	DM3O8QY	Moderate	Increased risk of ventricular arrhythmias by the combination of Formoterol and Degarelix.	Prostate cancer [2C82]	[61]
ABIRATERONE	DM8V75C	Moderate	Increased risk of ventricular arrhythmias by the combination of Formoterol and ABIRATERONE.	Prostate cancer [2C82]	[61]
Enzalutamide	DMGL19D	Moderate	Increased risk of prolong QT interval by the combination of Formoterol and Enzalutamide.	Prostate cancer [2C82]	[61]
Relugolix	DMK7IWL	Moderate	Increased risk of prolong QT interval by the combination of Formoterol and Relugolix.	Prostate cancer [2C82]	[61]
Bicalutamide	DMZMSPF	Moderate	Increased risk of ventricular arrhythmias by the combination of Formoterol and Bicalutamide.	Prostate cancer [2C82]	[61]
Levomepromazine	DMIKFEL	Moderate	Increased risk of ventricular arrhythmias by the combination of Formoterol and Levomepromazine.	Psychotic disorder [6A20-6A25]	[61]
Gatifloxacin	DMSL679	Moderate	Increased risk of prolong QT interval by the combination of Formoterol and Gatifloxacin.	Respiratory infection [CA07-CA4Z]	[61]
Ciclesonide	DM2NA4K	Minor	Increased risk of hypokalemia by the combination of Formoterol and Ciclesonide.	Respiratory system disease [CB40-CB7Z]	[59]
Dexamethasone	DMMWZET	Minor	Increased risk of hypokalemia by the combination of Formoterol and Dexamethasone.	Rheumatoid arthritis [FA20]	[59]
Quetiapine	DM1N62C	Moderate	Increased risk of ventricular arrhythmias by the combination of Formoterol and Quetiapine.	Schizophrenia [6A20]	[61]
Aripiprazole	DM3NUMH	Moderate	Increased risk of prolong QT interval by the combination of Formoterol and Aripiprazole.	Schizophrenia [6A20]	[68]
Iloperidone	DM6AUFY	Moderate	Increased risk of prolong QT interval by the combination of Formoterol and Iloperidone.	Schizophrenia [6A20]	[61]
Paliperidone	DM7NPJS	Moderate	Increased risk of ventricular arrhythmias by the combination of Formoterol and Paliperidone.	Schizophrenia [6A20]	[61]
Amisulpride	DMSJVAM	Moderate	Increased risk of ventricular arrhythmias by the combination of Formoterol and Amisulpride.	Schizophrenia [6A20]	[61]
Asenapine	DMSQZE2	Moderate	Increased risk of ventricular arrhythmias by the combination of Formoterol and Asenapine.	Schizophrenia [6A20]	[61]
Pimozide	DMW83TP	Moderate	Increased risk of prolong QT interval by the combination of Formoterol and Pimozide.	Schizophrenia [6A20]	[61]
LEE011	DMMX75K	Major	Increased risk of prolong QT interval by the combination of Formoterol and LEE011.	Solid tumour/cancer [2A00-2F9Z]	[69]
Vandetanib	DMRICNP	Moderate	Increased risk of prolong QT interval by the combination of Formoterol and Vandetanib.	Solid tumour/cancer [2A00-2F9Z]	[61]
Triptorelin	DMTK4LS	Moderate	Increased risk of ventricular arrhythmias by the combination of Formoterol and Triptorelin.	Solid tumour/cancer [2A00-2F9Z]	[61]
Doxorubicin	DMVP5YE	Moderate	Increased risk of ventricular arrhythmias by the combination of Formoterol and Doxorubicin.	Solid tumour/cancer [2A00-2F9Z]	[61]
Pitolisant	DM8RFNJ	Moderate	Increased risk of ventricular arrhythmias by the combination of Formoterol and Pitolisant.	Somnolence [MG42]	[61]
Telavancin	DM58VQX	Moderate	Increased risk of ventricular arrhythmias by the combination of Formoterol and Telavancin.	Staphylococcal/streptococcal disease [1B5Y]	[61]
Cabozantinib	DMIYDT4	Moderate	Increased risk of prolong QT interval by the combination of Formoterol and Cabozantinib.	Thyroid cancer [2D10]	[61]
Fluticasone	DMGCSVF	Minor	Increased risk of hypokalemia by the combination of Formoterol and Fluticasone.	Vasomotor/allergic rhinitis [CA08]	[59]
Procainamide	DMNMXR8	Moderate	Increased risk of prolong QT interval by the combination of Formoterol and Procainamide.	Ventricular tachyarrhythmia [BC71]	[61]
Flecainide	DMSQDLE	Moderate	Increased risk of prolong QT interval by the combination of Formoterol and Flecainide.	Ventricular tachyarrhythmia [BC71]	[61]
Amiodarone	DMUTEX3	Moderate	Increased risk of prolong QT interval by the combination of Formoterol and Amiodarone.	Ventricular tachyarrhythmia [BC71]	[61]

References

• [1] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 3465).
• [2] Long duration of airway but not systemic effects of inhaled formoterol in asthmatic patients. Respir Med. 2008 Mar;102(3):449-56.
• [3] Health Canada Product Monograph: Oxeze (formoterol) dry powder inhaler
• [4] FDA Approved Drug Products: Perforomist? inhalation solution
• [5] FDA Approved Drug Products: Foradil? Aerolizer inhalation powder
• [6] Formoterol. An update of its pharmacological properties and therapeutic efficacy in the management of asthma. Drugs. 1998 Feb;55(2):303-22.
• [7] Long-acting beta2-agonists for chronic obstructive pulmonary disease patients with poorly reversible airflow limitation. Cochrane Database Syst Rev. 2002;(3):CD001104.
• [8] Tocolytic effects of a long-acting beta2-adrenoceptor agonist, formoterol, in rats. J Pharm Pharmacol. 2000 Nov;52(11):1417-23.
• [9] Long-acting beta2-agonists for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2000;(2):CD001104.
• [10] Identification of novel substrates and structure-activity relationship of cellular uptake mediated by human organic cation transporters 1 and 2. J Med Chem. 2013 Sep 26;56(18):7232-42.
• [11] A comparison of the expression and metabolizing activities of phase I and II enzymes in freshly isolated human lung parenchymal cells and cryopreserved human hepatocytes. Drug Metab Dispos. 2007 Oct;35(10):1797-805.
• [12] FDA Label of Formoterol. The 2020 official website of the U.S. Food and Drug Administration.
• [13] Inhibitory effects of anticancer drugs on dextromethorphan-O-demethylase activity in human liver microsomes. Cancer Chemother Pharmacol. 1993;32(6):491-5.
• [14] Effect of genetic polymorphism on the metabolism of endogenous neuroactive substances, progesterone and p-tyramine, catalyzed by CYP2D6. Brain Res Mol Brain Res. 2004 Oct 22;129(1-2):117-23.
• [15] CYP2D6 polymorphisms and tamoxifen metabolism: clinical relevance. Curr Oncol Rep. 2010 Jan;12(1):7-15.
• [16] Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
• [17] Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
• [18] Inhibition of cytochrome P450 2D6: structure-activity studies using a series of quinidine and quinine analogues. Chem Res Toxicol. 2003 Apr;16(4):450-9.
• [19] Effects of propofol on human hepatic microsomal cytochrome P450 activities. Xenobiotica. 1998 Sep;28(9):845-53.
• [20] Pharmacogenetics of schizophrenia. Am J Med Genet. 2000 Spring;97(1):98-106.
• [21] Roles of CYP2A6 and CYP2B6 in nicotine C-oxidation by human liver microsomes. Arch Toxicol. 1999 Mar;73(2):65-70.
• [22] Structure-activity relationship for human cytochrome P450 substrates and inhibitors. Drug Metab Rev. 2002 Feb-May;34(1-2):69-82.
• [23] Progesterone and testosterone hydroxylation by cytochromes P450 2C19, 2C9, and 3A4 in human liver microsomes. Arch Biochem Biophys. 1997 Oct 1;346(1):161-9.
• [24] Tamoxifen inhibits cytochrome P450 2C9 activity in breast cancer patients. J Chemother. 2006 Aug;18(4):421-4.
• [25] Characterization of the oxidative metabolites of 17beta-estradiol and estrone formed by 15 selectively expressed human cytochrome p450 isoforms. Endocrinology. 2003 Aug;144(8):3382-98.
• [26] Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
• [27] Drug-drug interactions with imatinib: an observational study. Medicine (Baltimore). 2016 Oct;95(40):e5076.
• [28] Drug interactions with calcium channel blockers: possible involvement of metabolite-intermediate complexation with CYP3A. Drug Metab Dispos. 2000 Feb;28(2):125-30.
• [29] New insights into the structural features and functional relevance of human cytochrome P450 2C9. Part I. Curr Drug Metab. 2009 Dec;10(10):1075-126.
• [30] A potential role for the estrogen-metabolizing cytochrome P450 enzymes in human breast carcinogenesis. Breast Cancer Res Treat. 2003 Dec;82(3):191-7.
• [31] A mechanistic approach to antiepileptic drug interactions. Ann Pharmacother. 1998 May;32(5):554-63.
• [32] High-dose rabeprazole/amoxicillin therapy as the second-line regimen after failure to eradicate H. pylori by triple therapy with the usual doses of a proton pump inhibitor, clarithromycin and amoxicillin. Hepatogastroenterology. 2003 Nov-Dec;50(54):2274-8.
• [33] Cytochrome P450 pharmacogenetics and cancer. Oncogene. 2006 Mar 13;25(11):1679-91.
• [34] CYP2C19*17 is associated with decreased breast cancer risk. Breast Cancer Res Treat. 2009 May;115(2):391-6.
• [35] Cytochromes of the P450 2C subfamily are the major enzymes involved in the O-demethylation of verapamil in humans. Naunyn Schmiedebergs Arch Pharmacol. 1995 Dec;353(1):116-21.
• [36] Diclofenac and its derivatives as tools for studying human cytochromes P450 active sites: particular efficiency and regioselectivity of P450 2Cs. Biochemistry. 1999 Oct 26;38(43):14264-70.
• [37] Organic anion-transporting polypeptide B (OATP-B) and its functional comparison with three other OATPs of human liver. Gastroenterology. 2001 Feb;120(2):525-33.
• [38] Possible involvement of multiple human cytochrome P450 isoforms in the liver metabolism of propofol. Br J Anaesth. 1998 Jun;80(6):788-95.
• [39] Are organic cation transporters capable of transporting prostaglandins? Naunyn Schmiedebergs Arch Pharmacol. 2005 Aug;372(2):125-30.
• [40] Cisplatin and oxaliplatin, but not carboplatin and nedaplatin, are substrates for human organic cation transporters (SLC22A1-3 and multidrug and toxin extrusion family). J Pharmacol Exp Ther. 2006 Nov;319(2):879-86.
• [41] Pharmacologic markers and predictors of responses to imatinib therapy in patients with chronic myeloid leukemia. Leuk Lymphoma. 2008 Apr;49(4):639-42.
• [42] Organic cation transporters are determinants of oxaliplatin cytotoxicity. Cancer Res. 2006 Sep 1;66(17):8847-57.
• [43] Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
• [44] Implications of genetic polymorphisms in drug transporters for pharmacotherapy. Cancer Lett. 2006 Mar 8;234(1):4-33.
• [45] Upregulation of histone acetylation reverses organic anion transporter 2 repression and enhances 5-fluorouracil sensitivity in hepatocellular carcinoma
• [46] Comparison of type I and type II organic cation transport by organic cation transporters and organic anion-transporting polypeptides. J Pharmacol Exp Ther. 2001 Jul;298(1):110-5.
• [47] Organic cation transporters and their pharmacokinetic and pharmacodynamic consequences. Drug Metab Pharmacokinet. 2008;23(4):243-53.
• [48] Influx Transport of Cationic Drug at the Blood-Retinal Barrier: Impact on the Retinal Delivery of Neuroprotectants. Biol Pharm Bull. 2017;40(8):1139-1145.
• [49] Emerging drugs in chronic obstructive pulmonary disease. Expert Opin Emerg Drugs. 2009 Mar;14(1):181-94.
• [50] Potential of beta2-adrenoceptor agonists as add-on therapy for multiple sclerosis: focus on salbutamol (albuterol). CNS Drugs. 2002;16(1):1-8.
• [51] Arformoterol tartrate in the treatment of bronchoconstriction in patients with chronic obstructive pulmonary disease. Drugs Today (Barc). 2009 Jan;45(1):3-9.
• [52] Current therapeutic uses and potential of beta-adrenoceptor agonists and antagonists. Eur J Clin Pharmacol. 1998 Feb;53(6):389-404.
• [53] Pharmacogenetic tests in asthma therapy. Clin Lab Med. 2008 Dec;28(4):645-65.
• [54] Postischemic brain injury is attenuated in mice lacking the beta2-adrenergic receptor. Anesth Analg. 2009 Jan;108(1):280-7.
• [55] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [56] 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
• [57] Functional alpha1- and beta2-adrenergic receptors in human osteoblasts. J Cell Physiol. 2009 Jul;220(1):267-75.
• [58] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7353).
• [59] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare "Centro de informacion online de medicamentos de la AEMPS - CIMA.".
• [60] Adverse effects and complications of treatment with beta-adrenergic agonist drugs. Committee on drugs, the American Academy of Allergy and Immunology. J Allergy Clin Immunol 75 (1985): 443-9. [PMID: 2858503]
• [61] Bengtsson B, Fagerstrom PO "Extrapulmonary effects of terbutaline during prolonged administration." Clin Pharmacol Ther 31 (1982): 726-32. [PMID: 7042176]
• [62] Product Information. Northera (droxidopa). Chelsea Therapeutics Inc, Charlotte, NC.
• [63] Product Information. Cymbalta (duloxetine). Lilly, Eli and Company, Indianapolis, IN.
• [64] Product Information. Arcapta Neohaler (indacaterol). Novartis Pharmaceuticals, East Hanover, NJ.
• [65] Product Information. Zeposia (ozanimod). Celgene Corporation, Summit, NJ.
• [66] Product Information. Meridia (sibutramine). Knoll Pharmaceutical Company, Whippany, NJ.
• [67] Product Information. Macrilen (macimorelin). Aeterna Zentaris, Charleston, SC.
• [68] Cerner Multum, Inc. "Australian Product Information.".
• [69] Canadian Pharmacists Association.